Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. - Wikidata - wikimedia - TriplyDB

Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression.

Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression.

http://www.wikidata.org/entity/Q38674158

about

Amyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta pores Fundamental role of pan-inflammation and oxidative-nitrosative pathways in neuropathogenesis of Alzheimer's disease in focal cerebral ischemic rats Fundamental role of pan-inflammation and oxidative-nitrosative pathways in neuropathogenesis of Alzheimer's disease Natural Antibodies as Rheostats for Susceptibility to Chronic Diseases in the Aged Alzheimer's Disease: Mechanism and Approach to Cell Therapy Mouse models of frontotemporal dementia Intravenous immunoglobulin and Alzheimer's disease: what now?The role of tau in neurodegenerative diseases and its potential as a therapeutic target Prion-like properties of Tau protein: the importance of extracellular Tau as a therapeutic target Tau-targeted treatment strategies in Alzheimer's disease Metformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathy Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models Inflammatory process in Alzheimer's Disease Tau Biology and Tau-Directed Therapies for Alzheimer's Disease Immunotherapeutic approaches for Alzheimer's disease The Role of MAPT in Neurodegenerative Diseases: Genetics, Mechanisms and Therapy Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment.Roles of tau protein in health and disease.Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency The intersection of amyloid beta and tau at synapses in Alzheimer's disease Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis.Novel immunological approaches for the treatment of Alzheimer's disease.A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity Antibody-derived in vivo imaging of tau pathology.Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy Tau aggregation and its interplay with amyloid-β.PE859, a novel tau aggregation inhibitor, reduces aggregated tau and prevents onset and progression of neural dysfunction in vivo.Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice.Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies.Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies.Doubly Phosphorylated Peptide Vaccines to Protect Transgenic P301S Mice against Alzheimer's Disease Like Tau Aggregation.Stabilization of Microtubule-Unbound Tau via Tau Phosphorylation at Ser262/356 by Par-1/MARK Contributes to Augmentation of AD-Related Phosphorylation and Aβ42-Induced Tau Toxicity.Trans-cellular propagation of Tau aggregation by fibrillar species Distinct Therapeutic Mechanisms of Tau Antibodies: Promoting Microglial Clearance Versus Blocking Neuronal Uptake.Targeting protein aggregation for the treatment of degenerative diseases A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease.

P2860

Q26738355-C7CD9901-1025-4FAB-BB65-8453A1C7F2A7 Q26747585-A097D7A8-693A-4C21-A545-984883B44773 Q26748713-1B9738E6-B184-473E-93C8-6823439349CF Q26752508-0661678D-BE6D-4A49-9A7C-D8FA0EC9A7D9 Q26778149-2BBF69F5-1D01-4353-9F6C-87FBA0C7E4CC Q26829009-CCA4E1F5-40E0-432A-8100-16278CAF293F Q27000371-603B74C7-9BE4-4EA1-83FA-97D18ED0A538 Q27005032-C4A04F96-C844-4D21-835B-1B24769B0E96 Q27021159-CCBBC4D2-9B02-4DC2-8D65-DA9B8DC8F7DA Q27023429-025C744E-20E6-4F8B-8525-D01174600F83 Q27301246-BBBFB6A6-BA1F-4117-993A-27AB4A85D4F4 Q27308146-FA6766CF-7833-4C2B-9E8C-F9A1098EAAB1 Q27500412-20DBE174-0E92-4499-BFC9-FE4C8A5D9C42 Q28071398-82917F43-8CCF-48DF-8CC4-1C898F2B563A Q28081278-61649165-3D76-4B19-A17F-4A263212A538 Q28119005-B26B84F8-EBC3-42D7-B87F-0959C21CEA6B Q30669674-7C620CA3-0C59-49E4-9E65-FD3E8F5FE908 Q31024674-B68C9B12-5496-47A1-B89F-1F9EB3898346 Q33556068-4EDCE57D-EABB-47E8-9417-B68F1547CF98 Q33559303-E2C3695F-D0B2-4B41-B9C4-20B5E86D077E Q33640390-3C3DA55A-C6DA-4386-8BC6-3974D7DBCD89 Q34054680-B67E944B-616B-499B-BD68-C139EC449EEE Q34205027-864B61D9-BE87-48A3-A199-6E6D40BBCD46 Q34562675-8254FE3D-1F8A-42E4-9463-A9B5C77B1B7C Q34616539-E517D8D3-B59B-47FF-A2A0-299B2122D831 Q34664345-6E767D45-94FE-4180-AB27-AAC0C12C7B42 Q34701388-1D30664C-5DFF-4BB7-9427-CA64F312A43C Q34973787-27ADE6FD-C502-4711-89FB-167B43C5324A Q35008256-76984462-72D1-42F7-BB45-4C4840797E06 Q35058484-40C81380-7CB1-4CE1-9449-BDDD1919325B Q35204878-5C250CEB-B601-4985-B9BA-10AF6E06F5BE Q35624263-A2EF2A53-A749-4483-AF4C-ACDEA53D102D Q35684362-A654DB00-A81A-4E31-8754-7AE8CFC37A5F Q35745135-C1959592-314D-43CA-8761-C923D60219B3 Q35826638-AC709C74-B55F-4028-8FDB-DF9FC1FE77D6 Q35972860-D8303B6E-8669-4740-BBB7-0BF34FC497B6 Q36003836-B6E03ADF-A224-4820-8F6F-A6FF4AA2155C Q36065130-ADE5E916-2258-416A-8ECA-849045C24E68 Q36235980-17D11671-F611-4D4C-A20E-956CB8461D09 Q36240389-7A4FAD7E-D4BC-48A3-85D9-1F5541DBBEB6

P2860

Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression.

http://www.wikidata.org/entity/Q38674158

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Passive immunization with anti ...... delay of disease progression.

@en

type

label

Passive immunization with anti ...... delay of disease progression.

@en

prefLabel

Passive immunization with anti ...... delay of disease progression.

@en

P1433

Q38674158-E3806208-3D24-4281-A9C7-3547890D50D3

P1476

Q38674158-BC987975-2B79-4597-8823-BC31A8A4AA4F

P2093

Q38674158-1DB8E211-3CBF-45DD-B3F3-CEB3D833989D

Q38674158-2622C666-0C1B-416E-BFD0-BD7A232B2BC7

Q38674158-49EF788B-22F7-498B-B3B8-EFB1FD360253

Q38674158-53710E4F-BAB5-425A-821C-E4F42DDB5034

Q38674158-91E22C47-2BA1-46ED-9BE6-AD68F57F04AB

Q38674158-ADC10FD7-C274-40E7-9500-F99C8AB48D0E

Q38674158-AF697F91-F03C-4BFC-B3AE-63D08C3359C4

Q38674158-C1252579-E69F-41CD-BC7B-B42955A06332

Q38674158-C42B3BCB-79A2-46BA-8298-9322DCE0F6BB

Q38674158-F41F9BE6-BEA8-499A-99E4-58ECC2B3C5B3

P2860

Q38674158-059D0D11-AF07-4062-9767-0F96525C62C5

Q38674158-072577F2-617A-4560-B919-D8C8A82091F8

Q38674158-09A93C6A-3A61-4337-9857-2E05C259D751

Q38674158-0A4B7F14-7794-4E8C-AE48-CB085F76B805

Q38674158-1E374B2A-64AC-4831-ABBF-F2090C2F7D17

Q38674158-304E4E25-D28A-4A9D-8528-5D75E4CDCAE0

Q38674158-318A7B9F-BD32-4D99-B8DE-DD2EB90CAAE6

Q38674158-33E1FCE8-1BD1-404B-A87F-CCF6C948BC0A

Q38674158-3D0779B7-3B39-4C32-BC3F-E4D2011849C4

Q38674158-4083ACCE-5336-4C59-8045-0BF4A0B8766C

P304

Q38674158-0CE3344E-A47C-4930-82F8-C58AE46076BB

P31

Q38674158-A3D57ED5-D95B-4973-BB63-5E5C21E6AA28

P356

Q38674158-62B11279-BCB1-4EA8-9B67-45AE4AA8BC9C

P407

Q38674158-CF1F04E2-39FA-44A1-BB30-2C5D3647324E

P433

Q38674158-F4E8985F-1068-4BF7-AAB5-179149A0336A

P478

Q38674158-3F09C8DD-1124-4D14-8AEA-80E147E7D1BF

P50

Q38674158-66550ED9-56F1-4143-8DBB-3E675580A42E

Q38674158-E27300CC-B95F-418A-8D51-11967C650B86

P577

Q38674158-6F52129F-5606-421F-889D-096785D5F0F5

P698

Q38674158-40F33B85-CC37-4AE8-AB33-791261EBE931

P921

Q38674158-32E27D87-F8CA-4F9F-B042-2CA559382BD0

Q38674158-C499CD6F-4584-4082-A91A-2BAC840DE7A2

P932

Q38674158-F2BE0752-411E-45D1-9F41-CD96C4550F72

P356

JBC.M111.229633

P1433

Journal of Biological Chemistry

P1476

Passive immunization with anti ...... d delay of disease progression

@en

P2093

Claire V Cella

http://www.w3.org/2001/XMLSchema#string

Helen Sims

http://www.w3.org/2001/XMLSchema#string

Jenna Hanmer

http://www.w3.org/2001/XMLSchema#string

Martin Citron

http://www.w3.org/2001/XMLSchema#string

Michael J O'Neill

http://www.w3.org/2001/XMLSchema#string

Michael L Hutton

http://www.w3.org/2001/XMLSchema#string

Robert Kinley

http://www.w3.org/2001/XMLSchema#string

Su Wu

http://www.w3.org/2001/XMLSchema#string

Tracey K Murray

http://www.w3.org/2001/XMLSchema#string

Xiyun Chai

http://www.w3.org/2001/XMLSchema#string

P2860

Transmission and spreading of tauopathy in transgenic mouse brain

Active and passive immunotherapy for neurodegenerative disorders

Tau protein, the paired helical filament and Alzheimer's disease

Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17

Tau suppression in a neurodegenerative mouse model improves memory function

A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis.

An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice

Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model

Tau in cerebrospinal fluid: a sensitive sandwich enzyme-linked immunosorbent assay using tyramide signal amplification

Laboratory investigation of cerebrospinal fluid proteins.

P304

34457-34467

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M111.229633

http://www.w3.org/2001/XMLSchema#string

P407

P433

39

http://www.w3.org/2001/XMLSchema#string

P478

286

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-08-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21841002

http://www.w3.org/2001/XMLSchema#string

P921

P932

3190817

http://www.w3.org/2001/XMLSchema#string